Abstract: The present invention relates to aqueous, curable composition, comprising or consisting of A) at least one uretdione prepolymer, which comprises at least one uretdione group, and which is obtainable by reacting A1) at least one uretdione polyisocyanate having an isocyanate functionality of at least 2.0, whereby said uretdione polyisocyanate is obtained from at least one aliphatic polyisocyanate, with A2) at least one compound comprising at least one Zerewitinoff-active group, and A3) at least one reactant, which comprises at least one Zerewitinoff-active group and being different from A2 or which is H2O, preferably in the presence of at least one catalyst, to obtain the uretdione prepolymer, wherein the prepolymer has an acid number of at most 4 mg KOH/g, preferably determined according to DIN EN ISO 2114:2002-06 as 37 wt. % aqueous dispersion; and B) optionally at least one compound, which comprises at least one Zerewitinoff-active group; and C) at least one azolate-compound.

Abstract: Polyaddition products containing hydroxyl and uretdione groups, a process for their preparation, their use for the production of highly reactive polyurethane (PUR) powder coatings which are free from elimination products and which crosslink to give light-stable and weather-stable coating films of high gloss, and the powder coatings produced accordingly are provided.

Abstract: Polyaddition products containing hydroxyl and uretdione groups, a process for their preparation, their use for the production of highly reactive polyurethane (PUR) powder coatings which are free from elimination products and which crosslink to give light-stable and weather-stable coating films of high gloss, and the powder coatings produced accordingly are provided.

Abstract: The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Abstract: The invention relates to a method of preparing a polyisocyanate with at least one uretdione group by oligomerizing part of the isocyanate groups of isophorone diisocyanate in the presence of a catalyst which accelerates the dimerization of isocyanate groups, wherein the oligomerization catalyst comprises a saline compound comprising from 10 to 100 wt. % of 1,2,3- and/or 1,2,4-triazolate structures (calculated as C2N3; molecular weight=66) in the anion, and the products prepared by this method.

Abstract: This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.

Abstract: The compounds of formula I herein exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, for treating a patient suffering from, or subject to, a physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.

Abstract: The present invention relates to urethane acrylates, which may be cured with high-energy radiation, in which the urethane acrylates are the reaction product of a) a polyisocyanate component containing 20 to 100 mole %, based on the moles of the polyisocyanate component a), of iminooxadiazine dione group-containing polyisocyanate trimers corresponding to formula A  wherein R1, R2and R3 are the same or different and represent linear or branched, C4-C20 (cyclo)alkyl groups and X is the same or different and represents isocyanate groups or isocyanate group-containing radicals that also contain iminooxadiazine dione, isocyanurate, uretdione, urethane, allophanate, biuret or oxadiazine trione groups, wherein R1, R2 and R3 are attached to a nitrogen atom, with b) an alcohol component containing at least one monobasic, hydroxy-functional, linear or branched C1-C12 alkyl ester of (meth)acrylic acid.

Abstract: Novel Intermediates ##STR1## wherein R is a substituted or unsubstituted hydrocarbon residue or acyl group; X is an electron withdrawing group; Y.sup.1 and Y.sup.2, which are the same or different, are each independently oxygen or sulfur; and A is a substituted or unsubstituted, divalent hydrocarbon residue have potent reactivity, this being useful in preparing guanidine derivatives.

Abstract: The present invention relates to a polyisocyanate mixture containing isocyanate trimers provided thati) 30 to 100 mole percent of the trimers are iminooxadiazine diones B and ##STR1## ii) 0 to 70 mole percent of the trimers are isocyanurates A iii) less than 10 mole percent of the polyisocyanate mixture is of the uretone imine structural type, andiv) the ratio of the sum of the mole percents of trimers A and B to the mole percent of uretdiones is greater than 4:1whereinR.sup.1, R.sup.2 and R.sup.3 are the same or different and represent the groups obtained by removing an isocyanate group from an aliphatic, cycloaliphatic, aromatic and/or araliphatic isocyanate having an NCO content of less than 70% and/or their oligomers.

Abstract: Uretdione-functional polyaddition compounds of the formula: ##STR1## Y and Y' are O, NH, or NR.sup.5 ; n is 1-20;R is ##STR2## R.sup.1 is a divalent hydrocarbon radical of 2-16 carbon atoms; R.sup.2 is H, identical or different hydrocarbon radicals of 1-14 carbon atoms;R.sup.3, R.sup.4 and R.sup.5 are identical or different hydrocarbon radicals of 1-14 carbon atoms, by reacting IPDI uretdione with at least one reactant selected from the group consisting of diols, amino alcohols and diamines in a solution (L1) thereby forming the product (UD-DA) polyaddition compound, and adding the solution (L1) to a second solvent (L2) in which the uretdione polyaddition compound is insoluble, thereby precipitating said polyaddition compound (UD-DA).

Abstract: This invention relates to compounds of formula (IA), (IB), (IC) or (ID), wherein m, X, Z, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.14 and the dotted lines are as defined below, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of using them to treat Alzheimer's disease, age-associated memory impairment, Parkinson's disease and other central nervous system disorders. The claimed compounds have the ability to enhance the release of neurotransmitters such as acetylcholine, dopamine and serotonin.

Abstract: Pyridyl substituted .beta.-lactam compounds used in preparing taxane derivatives having a 3' pyridyl substituted C13 side chain.

Abstract: Disclosed are 1-, 6- and 2-substituted-1-carba-2-penem-3-carboxylic acids, a process for their preparation, pharmaceutical compositions comprising said compounds and a method of using them to treat bacterial infections.

Abstract: New nonionic radiographic contrast agents having the formula ##STR1## wherein Y is a single bond, ##STR2## R.sub.1, R.sub.1 ' and R.sub.2 are the same or different and are hydrogen, alkyl or hydroxyalkyl.Hydroxyalkyl refers to such alkyl groups having 1 or more hydroxy groups. Preferred hydroxyalkyl groups include: ##STR3## R.sub.3 and R.sub.4 are the same or different and are hydrogen, methyl or --CH.sub.2 CH.sub.2 OH; R.sub.5 is hydrogen, alkyl, --CH.sub.2 CH.sub.2 OH, CH.sub.2 OH or OH and R.sub.6 is alkyl, --CH.sub.2 CH.sub.2 OH, CH.sub.2 OH, OH or hydrogen and may be the same or different than R.sub.5 and m is zero or one, with the proviso that no methylene or methine carbon atom of the heterocyclic ring is attached to both a nitrogen and an oxygen atom with the additional proviso that when Y is a single bond, m is not zero. These new contrast agents are water soluble and have desirable low osmolality and anticoagulant properties.

Abstract: The invention relates to reaction products prepared from(a) organic polyisocyanates,(b) 0.005 to 0.9 equivalents of a C.sub.6-24 alcohol per equivalent of NCO or latent NCO present in component (a),(c) 0.1 to 0.995 mol of cyanamide per equivalent of NCO or latent NCO present in component (a), and(d) ammonia or a volatile amine as neutralizing agent for the cyanamide groups of component (c),with the proviso that the reaction products are free from polyester and polyether groups and from halogen atoms.

Abstract: Dispersants containing basic amine groups are passivated toward fluorohydrocarbon compositions by reaction with a passivating amount of a dicarboxylic acid or anhydride.

Abstract: A process is disclosed for the preparation of aralkyl mono- and diurethanes or ureas by carbamylmethylation, or acid-catalyzed addition at a temperature of 40.degree. C. to about 100.degree. C. of formaldehyde and esters of carbamic acid to aromatic hydrocarbons. Aralkyl carbamates and ureas formed by this process can be cracked directly to produce aralkyl diisocyanates, or hydrogenated and then cracked to produce aliphatic diisocyanates, or reacted directly with polyols to produce polyurethanes by functioning as blocked isocyanates.

Abstract: Prepare N-(amidoalkyl)imides by contacting an imide with a 2-oxazoline under reaction conditions, optionally in the presence of a solvent.

Abstract: A novel series of quinolone carboxylic acids for use as antibacterial agents are described. Methods for making the compounds, methods of using the compounds and compositions containing them are also described. Certain novel intermediates are also described.

Abstract: Novel polyamide block copolymers are provided which comprise a central block of a soft segment derived from the residue of a polymeric polyol or polycarboxylic acid joined to terminal hard segment polyamide blocks. The linkages which join the blocks are of a novel type and are the opened form of certain monoazetidine-2,4-dione rings.The block copolymers can be prepared very rapidly via anionically polymerizing lactams on to prepolymer soft segments containing terminal azetidine-2,4-dione rings.The speed with which the polymerizations can be carried out make the block copolymers particularly useful for the RIM preparation of molded parts.

Abstract: Novel coating compositions are disclosed which comprise aqueous dispersions of polyamine resins in the form of their acid salts along with azetidinedione crosslinking agents and other optional adjuvants.The compositions give rise to improved methods for the electrodeposition of heat-curable films on substrates.The compositions and methods find particular utility in the cathodic deposition of coatings and films on automotive parts and household appliances.

Abstract: Novel isocyanato-azetidinedione compounds are provided which have the formula ##STR1## wherein R and R.sub.1 can be independently selected from hydrogen and hydrocarbyl or can be joined together and along with the carbon to which they are attached represent a cycloalkane residue having 4 to 6 ring carbon atoms, y is an integer from 1 to 7 and X is a hydrocarbon radical having a valency of y plus one.The monoisocyanate compounds are used as intermediates to provide further novel azetidinedione containing derivatives in the form of azetidinedione-isocyanurates (II) and azetidinedione-urethanes (III).All three classes of compounds can be employed as acid scavenging agents for stabilizing various kinds of halogenated polymer systems. Notably, (I) and (III) form highly useful polyamide-polyureas and polyamide-polyurethanes respectively by reaction with organic polyamines.